More about

Infliximab

News
November 10, 2019
3 min read
Save

Price increases doubled public spending on biologic DMARDs

Price increases doubled public spending on biologic DMARDs

ATLANTA — Annual public spending by Medicare and Medicaid on biologic DMARDs more than doubled, from $5.3 billion in 2012 to $10.3 billion in 2016, largely due to post-market price increases, according to Natalie McCormick, PhD, of Massachusetts General Hospital and Harvard Medical School.

News
November 05, 2019
4 min watch
Save

VIDEO: How to identify, manage patients with high-risk ulcerative colitis

VIDEO: How to identify, manage patients with high-risk ulcerative colitis

SAN ANTONIO — In this video from the American College of Gastroenterology Annual Meeting, David T. Rubin, MD, section chief of Gastroenterology, Hepatology and Nutrition, and co-director of the Digestive Diseases Center at the University of Chicago Medicine, discusses his presentation on identifying and managing patients with high-risk ulcerative colitis.

News
September 30, 2019
1 min read
Save

Skin cancer biopsy rates among providers, top dermatology stories

Dermatologists performed the fewest number of biopsies to diagnose one skin cancer compared with other types of clinicians, according to researchers from University of Wisconsin-Madison and Mayo Clinic, in the top Healio Dermatology story last week.

News
September 25, 2019
1 min read
Save

Remicade 10 mg reasonable starting dose for hidradenitis suppurativa

For most patients with hidradenitis suppurativa, a dosage of at least 10 mg/kg of Remicade every 8 weeks will optimize treatment, according to findings published in Journal of the American Academy of Dermatology.

News
September 25, 2019
4 min read
Save

Q&A: VARSITY, UNIFI add to the armamentarium for ulcerative colitis

Q&A: VARSITY, UNIFI add to the armamentarium for ulcerative colitis

Physicians have an array of biologic agents available to treat patients with ulcerative colitis, but it is still unknown which therapies are superior, as well as which therapies work best in certain instances.

News
September 19, 2019
3 min read
Save

Adalimumab, IBI303 biosimilar demonstrate comparable safety, efficacy in AS

Adalimumab, IBI303 biosimilar demonstrate comparable safety, efficacy in AS

IBI303, a biosimilar to adalimumab developed by Chinese biopharmaceutical company Innovent Biologics, is comparable in safety and efficacy to the originator drug among patients with ankylosing spondylitis, according to data published in The Lancet Rheumatology.

News
August 28, 2019
2 min read
Save

Some patients prescribed biologics also receive topical medications for psoriasis

Some patients prescribed biologics also receive topical medications for psoriasis

In patients with psoriasis, the median time between first and last biologic prescriptions was between 3.3 and 7 months with up to 50% of patients not prescribed a second prescription for the medication, according to researchers in Journal of Drugs in Dermatology.

News
August 21, 2019
1 min read
Save

Four popular headlines to highlight Psoriasis Action Month

Four popular headlines to highlight Psoriasis Action Month

Earlier this month, Healio Dermatology posted a compilation of eight popular reads to kickoff Psoriasis Action Month in psoriasis research, advocacy and FDA news.

News
August 08, 2019
2 min read
Save

Complex rheumatology therapies require physicians, nurses to work together

Complex rheumatology therapies require physicians, nurses to work together

ORLANDO — As rheumatology treatments continue to advance and grow more complex, the need for teamwork among physicians, nurse practitioners, registered nurses and other health care professionals has never been more important, according to Adam J. Brown, MD, of the Cleveland Clinic.

View more